India's Anuh Pharma prequalified status suspended by WHO

Laboratory life science work

The World Health Organization (WHO) has suspended Mumbai-based Anuh Pharma as a prequalified supplier of active pharmaceutical ingredients (APIs) pyrazinamide, used to treat tuberculosis, and sulfadoxine, a malaria treatment, in the latest manufacturing-related blow for the firm.

Anuh, in a notice to the Bombay Stock Exchange, said the WHO's action followed a ban by the European Medicines Agency (EMA) for shipping antibiotic APIs from its Boisar site in the western state of Maharashtra, pending an inspection.

"In view of the EDQM suspension, the WHO prequalification authorities have suspended pyrazinamide and sulfadoxine from the WHO list of prequalified APIs until the WHO led inspection," Anuh Pharma said in the notice.


[Infographic] Machine Learning, Statistics and Optimizing Outcomes

In our infographic, we outline the potential of fusing machine learning and statistics algorithms together to more efficiently analyze clinical trial data output and ultimately revolutionize clinical research.

Anuh has previously pledged to fix problems cited at the plant that include failures to adequately detail the sources of antibiotic APIs as well as sourcing one product, azithromycin, from China's Hebei Dongfeng Pharmaceutical--a company banned in 2014 on good manufacturing practice violations from supplying the European Union.

Scores of Indian firms face manufacturing and data collection violations from EU inspectors and the U.S. FDA--mostly for generic medicines that are a crucial part of a supply chain aimed at keeping reimbursement costs in check in developed economies, and meeting demand for lower-cost products in emerging markets.

This also comes after WHO cited Ahmedabad-based Cadila Healthcare in March for rabies vaccine manufacture deficiencies at its Moraiya plant.

- here's the notice to the Bombay Stock Exchange
- and a story from Press Trust of India

Suggested Articles

Takeda sells €1.5 billion European drugs; top Indian drugmakers expand in China; Eisai moves closer to a quick Alzheimer’s blood test.

A buyer could emerge from private equity funds, European pharma players and Indian or Asian drugmakers looking to expand in Europe.

Leading Indian drugmakers Sun Pharma, Cipla, Aurobindo and Dr. Reddy's are all trying to expand their presences in China.